Quarterly Activities Report & Appendix 4C - 30 June 2017

• Revised BREVAGen plus ® commercial strategy attracting wider market interest • Achieved 64% samples growth for the quarter • Executed investigator initiated research Agreement with The Ohio State University • Advanced development of colorectal cancer risk assessment test • Maintained strong cash position with $11.0M in cash Melbourne, Australia, 27 July 2017: Genetic Technologies Limited (ASX: G